Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533416 | 0.88 | GPR52 (0.48) | GPR52 | |
| SCHEMBL16658711 | 0.80 | GPR52 (0.47) | GPR52 | |
| SCHEMBL15534344 | 0.80 | GPR52 (0.50) | GPR52 | |
| SCHEMBL15534342 | 0.80 | GPR52 (0.50) | GPR52 | |
| SCHEMBL23959499 | 0.80 | EPHX2 (0.49) | CTSKCTSSIDO1CA12CA1 | |
| SCHEMBL7966733 | 0.80 | CA12 (0.47) | SIGMAR1CTSKCTSSIDO1CA12 | |
| SCHEMBL572740 | 0.77 | IDO1 (0.60) | SIGMAR1CTSKCTSSIDO1CA12 | |
| SCHEMBL9608627 | 0.76 | GPR52 (0.41) | CTSKCTSSCTSLCTSBGPR52 | |
| SCHEMBL8837533 | 0.76 | CA12 (0.49) | SIGMAR1CTSKCTSSIDO1CA12 | |
| SCHEMBL4583679 | 0.76 | IDO1 (0.53) | SIGMAR1CTSKCTSSIDO1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852581-B1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2012069605-A1 | NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | TRPV1, TRPA1, P2RX3 | SIGMAR1 300/4885CTSK 254/4885CTSS 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.